A pan-genotype hepatitis C virus viral vector vaccine generates T cells and neutralizing antibodies in mice

Timothy Donnison1 | Joey McGregor2,3 | Senthil Chinnakannan1 | Claire Hutchings1 | Rob J. Center2,3 | Pantelis Poumbourios2,4 | Paul Kienerman1 | Heidi E. Drummer2,3,4 | Eleanor Barnes1,5

1Nuffield Department of Medicine, Peter Medawar Building for Pathogen Research, University of Oxford, Oxford, UK
2Burnet Institute, Melbourne, Victoria, Australia
3Department of Microbiology and Immunology at The Peter Doherty Institute for Infection and Immunity, University of Melbourne, Parkville, Victoria, Australia
4Department of Microbiology, Monash University, Clayton, Victoria, Australia
5Nuffield Department of Medicine, Jenner Institute, University of Oxford, Oxford, UK

Abstract

Background and Aims: A prophylactic vaccine targeting multiple HCV genotypes (gt) is urgently required to meet World Health Organization elimination targets. Neutralizing antibodies (nAbs) and CD4+ and CD8+ T cells are associated with spontaneous clearance of HCV, and each may contribute to protective immunity. However, current vaccine candidates generate either nAbs or T cells targeting genetically variable epitopes and have failed to show efficacy in human trials. We have previously shown that a simian adenovirus vector (ChAdOx1) encoding conserved sequences across gt1-6 (ChAd-Gt1-6), and separately gt-1a E2 protein with variable regions deleted (E2Δ123HMW), generates pan-genotypic T cells and nAbs, respectively. We now aim to develop a vaccine to generate both viral-specific B- and T-cell responses concurrently.

Approach and Results: We show that vaccinating with ChAd-Gt1-6 and E2Δ123HMW sequentially in mice generates T-cell and antibody (Ab) responses comparable to either vaccine given alone. We encoded E2Δ123 in ChAdOx1 (ChAd-E2Δ123) and show that this, given with an E2Δ123HMW protein boost, induces greater CD81-E2 inhibitory and HCV-pseudoparticle nAb titers compared to the E2Δ123HMW prime boost. We developed bivalent

Abbreviations: Ab, antibody; Ag, antigen; BSA, bovine serum albumin; ChAd, chimpanzee adenovirus; ChAdOx1, chimpanzee adenovirus Oxford 1 (licensed vector); E2, envelope 2 protein; GC, germinal center; Gt, genotype; HCVCc, HCV cell culture; HCVpp, HCV pseudoparticle; HMW, high molecular weight; ICS, intracellular cytokine staining; HVR, hypervariable region; ID50, median infective dose; IFN, interferon; MVA, modified vaccinia Ankara; nAb, neutralizing antibody; NS, nonstructural protein; RBD, receptor binding domain.

Timothy Donnison and Joey McGregor contributed equally.

Heidi E. Drummer and Eleanor Barnes are joint senior authors.

Funding information
Supported by the National Health and Medical Research Council (project grant: 1146082). H.E.D. was the recipient of a National Health and Medical Research Council Research fellowship (1041897). The Burnet Institute gratefully acknowledges support from the Victorian Operational Infrastructure Support program. E.B. was funded by the Medical Research Council UK (MR/K010239/1), the Oxford NIHR Biomedical Research Centre, and the Oxford Martin School (HCMIGGS1) and is an NIHR Senior Investigator. T.D. was a recipient of a Nuffield Department of Medicine (NDM; 1514261) DPhil Prize Studentship, a Medical Research Council (MRC) Supplementary Fund, and an MRC Confidence in Concept Fund (MC_
viral vector vaccines (ChAdOx1 and modified vaccinia Ankara [MVA]) encoding both Gt1-6 and E2Δ123 immunogens (Gt1-6-E2Δ123) generating polyfunctional CD4+ and CD8+ T cells and nAb titers in prime/boost strategies. This approach generated nAb responses comparable to monovalent E2Δ123 ChAd/MVA vaccines and superior to three doses of recombinant E2Δ123HMW protein, while also generating high-magnitude T-cell responses. **Conclusions:** These data are an important step forward for the development of a pan-genotype HCV vaccine to elicit T cells and nAbs for future assessment in humans.

**INTRODUCTION**

HCV currently infects >50 million persons and, despite the rollout of efficacious directly acting antiviral (DAA) drugs, remains endemic in many countries. The World Health Organization has set targets for HCV elimination by 2030. However, estimates suggest that most (>60%) countries will fail to meet these targets,[1,2] and therefore a vaccine will be essential for HCV elimination. In support of vaccine efforts, mathematical models of HCV transmission suggest that a prophylactic vaccine that was only 30% effective would significantly reduce HCV incidence used alongside diagnostics and DAA therapy.[3–5] Given that liver disease caused by HCV requires chronic infection, the aim of a prophylactic vaccine should be to prevent chronic infection, rather than providing sterilizing immunity.

Spontaneous clearance occurs in 20% of primary HCV infections,[6] and these persons are more likely to clear subsequent infections.[7] Although the immune correlates that confer HCV resolution are not completely understood, data suggest that both T-cell and antibody (Ab) responses play a crucial role in HCV clearance. These include the association of viral clearance with class I and II human leukocyte antigens,[8] detection of broad polyfunctional T cells,[9] and the early appearance of broadly neutralizing Abs.[10,11] Furthermore, T-cell blocking studies in chimpanzees highlight the importance of a synergistic CD4+ and CD8+ T-cell response.[12,13] The optimal HCV vaccine should generate protective humoral and cellular responses and be affordable and practical, both in terms of manufacture and delivery. Current vaccine efforts have primarily focused on either inducing Abs targeting HCV surface envelope glycoproteins (gpE1E2[14–17]) to block viral entry or activating T cells to destroy HCV-infected cells.[18–20] Vaccine development is challenged by HCV genetic diversity that facilitates viral escape from Abs and T cells. Only two vaccines have advanced to human trials,[15–20] and both have elicited immune responses to antigens (Ags) that display high sequence diversity and are prone to mutational escape (reviewed by Bailey et al.[21]). One of these used a chimpanzee adenovirus (ChAd) vector (ChAd3) and modified vaccine Ankara (MVA) vector prime/boost strategy, encoding an HCV gt-1b nonstructural (NS) sequence generating high-magnitude, polyfunctional CD4+ and CD8+ T cells.[20] These T cells predominantly targeted gt-1b epitopes that exhibited high sequence variability with limited reactivity to non-1b genotypes (gts)[20,22] and failed to prevent chronic HCV in a phase II clinical trial.[23] The other vaccine consists of recombinant full-length gt-1a gpE1E2 protein. Despite the generation of high-Ab titers, neutralizing antibodies (nAbs) against heterologous HCV pseudoparticles (HCVpp) were generated in a minority of healthy volunteers in a phase I human trial.[15–17] These data show that alternative vaccine strategies that target multiple HCV gts, generating both nAbs and CD4+/CD8+ T cells, are urgently required to maximize the chances of vaccine efficacy.

We have previously described the development of a chimpanzee adenovirus Oxford 1 (ChAdOx1) vector encoding conserved HCV sequences across gt-1 to -6 (ChAd-Gt1-6) that generates robust T-cell responses targeting conserved epitopes in mice.[24,25] We also generated an Ab vaccine using a modified HCV gpE2 vaccine candidate with deletions of hypervariable domains, hypervariable region (HVR) 1, HVR2, and intergenotypic variable region (IgVR) presented as a disulfide-linked, high-molecular-weight (HMW) antigen (E2Δ123HMW). When used to immunize guinea pigs, E2Δ123HMW increased sera-neutralizing activity against heterologous HCV strains by targeting conserved epitopes on the neutralizing face of the envelope 2 protein (E2) receptor binding domain (RBD).[26] Here, we describe vaccine strategies to combine these two HCV vaccines to generate immune responses to conserved epitopes, including sequential vaccinations and heterologous prime-boost using both protein, ChAd, and MVA vectors to determine the optimal strategy for generating cross-genotype T- and B-cell responses.
MATERIALS AND METHODS

Viral vector vaccine nomenclature

The ChAdOx1 and MVA vector designs (Figure S1) encode either: (1) the conserved HCV sequence segment of gt-1 to -6 (Gt1-6)\(^{[25]}\); (2) the \(E2_{\Delta123}\) sequence; or (3) a bivalent immunogen encoding the Gt1-6 and \(E2_{\Delta123}\) sequences.

Protein vaccine nomenclature

The recombinant protein, \(E2_{\Delta123}\), encodes E2\(^{384-661}\) with deleted HVR1 (E2\(^{384-409}\)), HVR2 (E2\(^{460-485}\)), and IgVR (E2\(^{570-580}\)) sequences (Figure S2A). The HMW \(E2_{\Delta123}\) species is called \(E2_{\Delta123}\)\(_{HMW}\), and the monomer is called \(E2_{\Delta123}\). The recombinant monomeric protein, \(E2_{RBD}\), is wild type (WT) and encodes E2\(^{384-661}\), the full length of the E2 receptor binding domain. Both \(E2_{\Delta123}\)\(_{HMW}\) and \(E2_{RBD}\) proteins have a C-terminal polyhistidine tag for purification and application in assays. The \(E2_{\Delta123}\) and \(E2_{RBD}\) sequences were designed from Genbank sequence AF\(^{009606}\).

Vaccine production

A human codon optimized HCV immunogen was inserted into the donor vector between the cytomegalovirus promoter and bovine growth hormone poly-A sequence by In-Fusion cloning to generate the shuttle vector. The shuttle vector was cloned into the ChAdOx1 destination vector, using ThermoFisher’s LR gateway cloning method, and linearized using \(PmeI\) restriction and transfected into T-REx-293 cells (ThermoFisherScientific) to generate ChAdOx1 vaccines. For MVA vaccines, the HCV immunogen was cloned at the F11 locus of the pMVA-shuttle vector and the recombinant MVA generated by recombining the pMVA-shuttle vector and WT MVA. HCV viral vector vaccines were manufactured by the Viral Vector Core Facility (Jenner Institute, University of Oxford, Oxford, UK).

Recombinant proteins were expressed using the Freestyle 293-F cells stable transfected cell clone, purified from the culture supernatants using cobalt-charged TALON metal affinity resin (Clontech) by the C-terminal polyhistidine tag followed by size-exclusion chromatography on a Superdex200 prep grade 16/600 column (GE Healthcare), using the ÄKTA pure fast protein liquid chromatography system (GE Healthcare) equilibrated in PBS (pH 6.8). Fractions containing the HMW species were pooled and concentrated through an Amicon\(^{®}\) 30-kDa molecular-weight cut-off ultracentrifugal device (Merck).

Animal experiments

Mouse studies were performed at the Biomedical Services Building (BSB), Oxford, according to UK Home Office Regulations (project license numbers P874AC0F0 and PP3430109) and approved by the ethical review board at the University of Oxford. All experiments complied with the ARRIVE (Animal Research: Reporting of In Vivo Experiments) guidelines and UK Animals (Scientific Procedure) Act, 1986. Groups of 4-12 age-matched 6- to 8-week-old female C57BL/6 mice were used throughout and housed at a pathogen-free facility in individually vented cages and fed a nutrient diet (Harlan Teklad Lab Blocks). Mice were vaccinated 1 week after arrival (i.m., 26-G needle; during light cycle; nonblinded) and culled postvaccination by schedule-1 (CO\(_2\) exposure followed by cervical dislocation or heartbeat cessation).

Organ isolation and processing

Terminal bleeds (cardiac puncture) were refrigerated at 4°C and sera isolated within 24 h. Spleens were mechanically processed using a sterile plunger and a 40-\(\mu\)m cell strainer. Splenic red blood cells were lysed with ACK (Ammonium-Chloride-Potassium) Lysis Buffer (ThermoFisherScientific) for <1 min and remaining cells resuspended in R10 media (RPMI-1640 media with L-glutamine [5%], penicillin-streptomycin [5%], and 10% fetal calf serum). Cell yields were calculated using a Guava Personal Cell analysis system (Merck Millipore 0100-14230) and the Muse Cell Analyser (Merck Millipore).

Peptides and Antibodies

HCV genotype-1a (H77; Genbank NC_038882), -1b (J4; Genbank AF054250), and -3a (K3a650; Genbank D28917) peptides of 15-18 amino acids, overlapping by 11 amino acids spanning the whole HCV proteome (optimal for CD4\(^{+}\) and CD8\(^{+}\) T-cell activation) were obtained from the National Institutes of Health (Bethesda, MD) and used in T-cell assays. Each peptide was initially dissolved in DMSO (40 mg/ml) and combined into nine peptide pools (300 \(\mu\)g/ml) covering the sequences of: Core, E1, E2, NS3p, NS3h, NS4, NS5a, NS5bI (aa2421-2718 in H77 reference sequence), and NS5bII (aa2719-3011). Synthetic peptides for ELISAs were synthesized (Genscript) and contained an N-terminal biotin group for avidin capture (Table S1). Antibodies used are described in Table S2.
**Ex vivo IFNγ Enzyme-Linked Immunospot**

*Ex vivo* detection of interferon (IFN)γ by HCV-stimulated splenocytes with enzyme-linked immunospot assays were performed as described.[24] Total and peptide-pool-specific (IFNγ+ spot forming units) responses were background subtracted and plotted per 10^6 splenocytes.

**Intracellular cytokine staining**

Intracellular cytokine staining (ICS) was performed as described.[24] Gating/analysis were performed in FlowJo (v10.7; TreeStar, Ashland, OR). Cytokine coexpression within T-cell subsets was determined using Boolean gating in FlowJo and graphs produced in Pestle (v2.0), and SPICE (v6.0; NIAID, NIH).

**ELISA**

Direct-binding assays and synthetic peptide ELISAs were performed as described.[27] Antibody titers were calculated as the reciprocal dilution of serum required for a 10-fold increase over binding to bovine serum albumin.

**Antibody isotype assay**

Antibody isotype assays were performed as described for ELISAs, with the addition of goat antimouse -IgG1, -Ig2a, -Ig2b, -Ig3, -IgA, and -IgM added at a 1:1000 dilution in 0.5% BSA in PBS containing 0.05% Tween 20 (BSA5PBST; 1 mg/ml)/well (Mouse Monoclonal Ab Isotyping Reagent Kit; Sigma-Aldrich) after addition of the serum. Bound Abs were detected with antigoi horseradish peroxidase (HRP) (Invitogen). Positive controls were mAb44 (IgG1 control), mAb25 (IgG2a control), mAb24 (IgG2b control), and mAb64 (IgG3) anti-HCV Abs at 1 μg/ml in BSA5PBST.

**CD81-LEL inhibition assay**

The ability of immune serum to prevent the interaction between E2 and recombinant CD81-LEL has been described,[27] with the exception that bound E2 was detected by using humanized mouse mAb2A12 followed by polyclonal goat antihuman HRP-conjugated Ab (Dako). Data was analyzed using GraphPad Prism software (v9.0; GraphPad Software Inc., La Jolla, CA) where inhibitory titers were expressed as the reciprocal dilution of immune serum that reduces the binding reaction being competed by 50% (median infective dose [ID_{50}]) where binding in the absence of sera is equivalent to 100% binding.

**HCVpp and cell-culture neutralization assay**

HCV neutralization assays were performed as described.[28] Briefly, HEK293T cells were cotransfected in a 1:1 (w/w) ratio of pE1E2H77c (gt-1a; Genbank AF011751) or pUKN3A1.9 (gt-3a; Genbank AY734985) and pNL4–3.LUC.R-E to produce HCVpp. Alternatively, infectious HCV cell culture (HCVcc)–derived genotype 3a (S52; Genbank EU204645), and 5a (SA13; Genbank FJ393024) were produced by transfecting Huh7.5 cells with *in vitro*–transcribed RNA by electroporation,[26] with the modification that luciferase activity was measured in a microplate reader (ClarioSTAR; BMG Labtechnologies). Mean percentage entry was calculated as (relative light units [RLU] plasma + virus)/(RLU medium+virus) × 100. Percentage entry was plotted against the reciprocal dilution of plasma in GraphPad Prism software (version 9; GraphPad Software) and curves fitted with a one-site specific binding Hill plot. The reciprocal dilution of plasma required to prevent 50% virus entry was calculated from the nonlinear regression line (ID_{50}). The lowest amount of nAb detectable was a titer of 40. Samples that did not reach 50% neutralization were assigned an arbitrary value of 20.

**Statistical analysis**

Data were analyzed using GraphPad Prism (v9.0; GraphPad Software). Nonparametric Mann-Whitney U or Kruskal-Wallis tests with multiple comparisons were used to determine significant differences between group medians at 95% CIs. *p* values <0.05 indicate a significant difference: *p* < 0.05; **p* < 0.01; ***p* < 0.001; ****p* < 0.0001.

**RESULTS**

**ChAd-E2Δ123 prime increases CD81 binding inhibition and nAb titers**

Sequential administration of ChAd-Gt1-6 and E2Δ123_HMW protein did not alter the immune response to either vaccine (Figures S1–S3). Therefore, we developed viral vectors that encode the E2Δ123 sequence alongside T-cell immunogens, to develop a single-viral–vectored vaccine to prime both T- and B-cell responses. First, we generated a ChAdOx1 vector encoding the E2Δ123 sequence (Figure S1B) and measured Ab titers specific for E2Δ123 and neutralization epitopes, Ab neutralizing capacity, and Ab isotype profile and compared these to responses generated with E2Δ123_HMW protein vaccine. We used homologous (three ChAd-E2Δ123 or E2Δ123_HMW protein vaccines only; groups 1 and 2) and heterologous
(ChAd-E2Δ123 prime with two E2Δ123HMW protein boosts; group 3) prime-boost-boost regimens (Figure 1A). The ChAd-E2Δ123 vaccine induced Ab titers at 3 weeks postprime that were significantly higher than with the E2Δ123HMW protein vaccine (**p = 0.0007; Figure 1B). However, after subsequent booster vaccinations at week 3 and week 6, homologous E2Δ123HMW immune sera displayed greater Ab titers than homologous ChAd-E2Δ123 immune sera (**p = 0.0065 [week 6] and ***p < 0.0001 [week 8] for group 1 vs. group 2; Figure 1B). Groups boosted with E2Δ123HMW protein (groups 2 and 3) induced significantly higher week 8 Ab titers compared to their week 3 preboost titers, whereas the homologous ChAd-E2Δ123 regimen (group 1) induced significantly higher week 8 Ab titers after a prime and boost (Figure S4A). Mice immunized with E2Δ123HMW protein vaccine (groups 2 and 3) displayed significantly greater Ab titers to AS412 (E2408-428), AS434 (E2430-451), and the CD81 binding loop (E2523-549) compared to mice immunized with ChAd-E2Δ123 alone (Figure 1C). Strikingly, mice that received a ChAd-E2Δ123 prime vaccination followed by two E2Δ123HMW boost vaccinations (group 3) displayed greater inhibitory and gt-1a neutralization titers compared to the homologous regimens (E2-CD81 ID50: **p = 0.0016 for group 1 vs. group 3 and ***p = 0.0001 for group 2 vs. group 3; HCVpp ID50: **p = 0.0013 for group 1 vs. group 3 and *p = 0.0113 for group 2 vs. group 3, Figure 1D; 80% inhibitory dose in Figure S4B). When ID50 titers (CD81 inhibition and HCVpp) were assessed in relation to the overall Ab titer (functional Ab index: ID50/Ab titer), the ChAd-E2Δ123 immune sera (groups 1 and 3) had a significantly higher functional index compared to E2Δ123HMW immune sera, indicating a qualitative enhancement of the vaccine-induced Ab response (Figure 1E). When analyzing the Ab response by isotype, regimens with an E2Δ123HMW protein vaccine boost generated higher titers across all isotypes compared to the homologous ChAd-E2Δ123 regimen (Figure S4C), in line with the overall Ab titers. However, the ChAd-E2Δ123 prime, E2Δ123HMW protein boost (group 3) regimen generated a higher IgG2a titer (*p = 0.0103 for group 2 vs. group 3; Figure S4C) and, overall, a broader isotype repertoire (Figure 1F). When the IgG2a titer was expressed as a function of the IgG1 titer (IgG1/IgG2a), ChAd-E2Δ123 immune sera (groups 1 and 3) had a significantly lower reciprocal titer compared to E2Δ123HMW immune sera, indicative of increased germinal center (GC) processing (****p < 0.0001 for group 1 vs. group 2; **p = 0.0032 for group 2 vs. group 3; Figure 1G). Finally, for E2Δ123HMW immune sera (groups 2 and 3 combined), the IgG1:IgG2a reciprocal titer positively correlated with HCVpp-neutralizing titers (r = 0.4072; p = 0.0483; Figure 1G). Overall, encoding E2Δ123 in ChAdOx1 enhanced the quality of the Ab response and, when combined with E2Δ123HMW protein boosts, generated high functional Ab titers.

**Bivalent vaccines are as immunogenic as monovalent vaccines**

The ability to generate a robust Ab response to E2Δ123 using viral vectors suggests that it is possible to engineer a viral vector to deliver both HCV-specific T- and B-cell Ags. Therefore, we designed ChAdOx1 and MVA vector vaccines that encode both the Gt1-6 and E2Δ123 HCV sequences in a single immunogen (Gt1-6-E2Δ123; Figure S1C,F) to generate nAbs and T cells targeting multiple HCV gts.

In mice, a week 0 ChAd prime and week 4 MVA boost vaccine (the regimen referred to as “prime/boost” hereon in and shown as a schematic in Figure 2A), encoding either a (1) monovalent E2Δ123 immunogen (design in Figure S1B,E) or (2) bivalent Gt1-6-E2Δ123 immunogen (design in Figure S1C,F), was administered. Both regimens generated similar titers of Abs binding E2Δ123 and the AS434 (E2430-451) neutralization epitope (Figure 2B), inhibiting CD81-E2 binding and neutralizing both homologous and heterologous HCVpp (gt-1a and -3a, ID50) at 2 weeks post-MVA vaccination (Figure 2C; ID80 in Figure S5A). However, monovalent vaccine immune sera displayed greater titers of Abs targeting neutralization epitopes AS412 (E2408-428) and the CD81 binding loop (E2523-549; Figure 2B), compared to animals that received the bivalent vaccine. Furthermore, more animals within the prime/boost monovalent vaccine group generated nAb activity compared to those in the prime/boost bivalent vaccine group (7 of 10 vs. 3 of 10, respectively, for gt-1a; 6 of 10 vs. 2 of 10, respectively, for gt-3a; Figure 2C).

When assessing T-cell responses, the prime/boost monovalent vaccine group generated a significantly higher E2-specific CD8+ T-cell response (gt-1a, but not gt-1b) compared to the prime/boost bivalent vaccine group (**p = 0.0003; Figure 2D). Conversely, the prime/boost bivalent vaccine group generated greater CD4+ and CD8+ T cells specific for nonstructural proteins (NS) 3-4 and NS5 peptide pools (both gt-1a and -1b peptide variants) than the prime/boost monovalent vaccine group (Figure 2D; core/E1-specific responses were undetectable: Figure S5B). All CD8+ T cells displayed similar polyfunctionality, whereas monovalent vaccine-induced CD4+ T cells had increased polyfunctionality (Figure S5D). When comparing the prime/boost bivalent vaccine regimen (group 4) against the prime/boost monovalent T-cell vaccine regimen (group 3; ChAd-Gt1-6/MVA-Gt1-6), the prime/boost bivalent vaccine group induced greater T-cell responses to NS3-4 (gt-1a; CD8+ T cells) and NS5 (gt-3a; CD4+ and CD8+ T cells) and, overall, a significantly higher total.
HEPATOLOGY

**Figure 1** Immunogenicity of an E2Δ123 protein sequence encoded in a ChAdOx1 prime vaccine. (A) Groups of 12 age-matched female C57BL/6 mice were vaccinated with a prime vaccine at day 0, a boost vaccine at week 3 (W3), and another boost vaccine at week 6 (W6), followed by a terminal bleed at week 8 (W8). Group 1 had three sequential ChAdE2Δ123 vaccinations; group 2: three sequential E2Δ123HMW protein vaccinations; and group 3: a ChAd-E2Δ123 prime followed by two sequential E2Δ123HMW protein boosts. ChAdE2Δ123 was given i.m. in the left quadricep at 10^5 infectious units (IU) in 40 μL sterile PBS. E2Δ123HMW (20 μg) was mixed 1:1 with 50 μL of Addavax® adjuvant and administered s.c. in the scruff of the neck. (B) Sera was collected at week 3 (preboost 1; hash indicates pooled groups 1 and 3), week 6 (preboost 2), and at week 8 (end of study; EOS) to determine the Ab titers’ capacity to bind gt-1a E2Δ123 monomer in an ELISA. (C) Immune sera’s (W8, EOS) capacity to bind CD81 binding determinants: AS412 (E2408-428); AS434 (E2430-451); and CD81 binding loop (E2523-549). ELISA Ab titers were measured at 10 times background (BSA), using dilution curves, and are plotted as log reciprocal titers. (D) EOS immune sera titers that inhibit 50% (ID50) of: E2 binding to CD81; neutralizing HCV gt-1a HCVpp; and HCV gt-3a and -5a HCVcc virion entry into Huh7.5 cells. ID50 inhibitory titers were determined using a dilution curve where the vaccine-induced Ab response was background subtracted and standardized to a negative control, which displayed 100% binding/entry (e.g., BSA, instead of immune sera, incubated with E2 or HCVpp/cc before determining CD81 binding or cell infectivity). (E) ID50 inhibitory titer of immune sera as a function of the overall Ab titer, displayed as Ab titer divided by ID50 titer. (F) EOS E2-specific Ab isotype titers are displayed as a fraction of the total Ab titer (median pie base). (G) IgG2a titer of immune sera was calculated as a function of the IgG1 titer and is displayed as IgG1/IgG2a class switching. The reciprocal titer (1/IgG1/IgG2a) was plotted against the HCVpp ID50 titer for immune sera from animals that received C/P/P and P/P/P to determine any correlation. All bars are medians, and interquartile ranges are displayed. For Panel B–D, the dashed line is the cutoff for detectable responses. The D’Agostino and Pearson test was used to determine normality of data distribution, and Mann-Whitney U tests were performed to determine significant differences between two group medians at a 95% CI (Kruskal-Wallis test for multiple groups). *p values indicate a significant difference between groups when: *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001

of gt-1a- and gt-1b-specific IFNγ+ CD8+ T-cell (gt-1a, **p = 0.0047; gt-1b, *p = 0.0379; Figure 2E) and gt-3a IFNγ+ CD4+ T-cell responses compared to the prime/boost monovalent vaccine group (*p = 0.041; Figure 2E). All T cells exhibited polyfunctionality (Figure S5E). The gating strategy for all ICS data is shown (Figure S5F).
FIGURE 2  Immunogenicity of a bivalent HCV vaccine immunogen (Gt1-6-E2Δ123) compared to monovalent immunogens, Gt1-6 and E2Δ123, in a ChAdOx1 prime, MVA boost regimen. Two experiments—each consisting of two groups of age-matched female C57BL/6 mice (n = 10)—were conducted. (A) The first experiment consisted of a week 0 ChAd-E2Δ123 prime (10⁸ infectious units [IU] in 40 μL of sterile PBS) followed by a week 4 MVA-E2Δ123 (10⁸ plaque-forming units [PFU] in 40 μL of sterile PBS group 1, green dots) versus a week 0 ChAd-Gt1-6-E2Δ123 prime followed by a week 4 MVA-Gt1-6-E2Δ123 (group 2, gray dots), all with Abs and splenic T cells analyzed at week 6 (week 2 post-MVA). The second experiment compared the peak T-cell response (week 1 post-MVA, i.e., week 5 post-ChAd) of a ChAd-Gt1-6 prime followed by an MVA-Gt1-6 (group 3, orange dots) versus a week 0 ChAd-Gt1-6-E2Δ123 prime followed by a week 4 MVA-Gt1-6-E2Δ123 (group 4, gray dots). In both experiments, ChAd and MVA vaccines were delivered via i.m. at 10⁸ infectious units and 10⁷ plaque-forming units, respectively, in the left quadriceps. (B) Group 1 and 2 immune sera were assessed for reactivity to E2Δ123 monomer and AS412 (E2408-428), AS434 (E2430-451), CD81 binding loop (E2452-549), and (C) capacity to inhibit 50% of the binding of CD81 to E2 binding and neutralization of gt-1a HCVpp virion entry into Huh7.5 cells. ID₅₀ inhibitory titers were determined using a dilution curve where the vaccine-induced Ab response was background subtracted and standardized to a negative control, which displayed 100% binding/entry (e.g., BSA, instead of immune sera, incubated with E2 or HCVpp before determining CD81 binding or cell infectivity). (D,E) Group 1 and 2 splenocytes were harvested at week 6 (D) and group 3 and 4 splenocytes at week 5 (E) and all stimulated ex vivo using HCV peptides (15 mer overlapping by 11 aa) covering the length of the HCV proteome (total) and for peptide pools: Core-E1-E2, NS3-4, and NS5, for gt-1a (H77), -1b (J4), or -3a (k3a650). IFNγ⁺ CD8⁺ and CD4⁺ T-cell frequencies as a percentage of total CD8⁺ or CD4⁺ T-cell frequencies were determined by intracellular cytokine staining and flow cytometry. All data are plotted as medians and interquartile ranges. For panel B and C, the dashed line is the cutoff for detectable responses. The D’Agostino and Pearson test was used to determine the normality of data distribution, and Mann-Whitney U tests were performed to determine significant differences between two group medians at a 95% CI. p values indicate a significant difference between groups when: *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001. aa, amino acids
with representative plots given (Figure S5G). These data suggest that a bivalent vaccination approach to induce HCV-specific T cells may be preferable to using a monovalent T-cell vaccine alone.

A bivalent ChAd prime, MVA boost generates higher-magnitude T cells and Ab titers than three E2Δ123HMW protein vaccines

We next assessed mixed-modality regimens using bivalent viral vector and E2Δ123HMW protein vaccines in a week 0 prime (W0), week 8 boost (W8), and week 20 (W20) boost vaccination regimen (prime/boost/boost). For simplicity, vaccines are denoted “C” (ChAd-Gt1-6-E2Δ123), “M” (MVA-Gt1-6-E2Δ123), and “P” (E2Δ123HMW protein); (Figure 3A). C/M/M and C/M/P vaccine immune sera displayed greater anti-E2Δ123 Ab titers at week 8 (preboost 1) compared to P/P/P vaccine immune sera (Figure 3B; \( \text{p} = 0.0247 \) and \( \text{p} = 0.0037 \), respectively). At week 22, C/M/M vaccine immune sera displayed significantly greater anti-E2Δ123 Ab titers compared to C/M/P vaccine immune sera (Figure 3B; \( \text{p} = 0.038 \)). Furthermore, week 22 C/M/M immune sera displayed significantly higher Ab titers targeting neutralization epitopes AS412 \((E2_{408,438})\) and AS434 \((E2_{430,451})\) compared to C/M/P and P/P/P (Figure S6A). No difference was observed between C/M (week 10) and C/M/M (week 22) Ab titers, but both regimens generated higher Ab titers than C/M/- (week 22), suggesting an Ab titer decline after the initial boost (Figure 3C).

Greater nAb titers against HCVpp(1a) were observed at week 12 after the first boost compared to week 22 after the second boost (Figure 3D; and Figure S6B). Only the P/P/P regimen generated higher nAb titers at week 22 compared to week 12, although these titers were low and not significantly different between time points (Figure S6B). Strikingly, week 12 nAb titers were greater in mice that received the ChAd-Gt1-6-E2Δ123/MVA-Gt1-6-E2Δ123 vaccines compared to mice that received two E2Δ123HMW protein vaccines (gt-1a, \( \text{p} = 0.0365 \); Figure 3E), with no differences detected between regimens at week 22. This trend was also observed in CD81-E2 inhibitory titers, although it was not statistically significant (Figure S6C).

Last, the C/M/M regimen generated greater IFN\( \gamma^+ \) T-cell frequencies compared to C/M/P and P/P/P regimens (CD8: Figure 3F, \( \text{p} = 0.0307 \) and \( \text{p} = 0.0006 \); CD4: Figure 3G, \( \text{p} = 0.0297 \)). C/M/M-induced CD8\(^+\) T cells were predominantly polyfunctional (IFN\( \gamma^+ \) and TNF\( \alpha^+ \)) in contrast to C/M/P CD8\(^+\) T cells (monofunctional), whereas CD4\(^+\) T cells from both regimens displayed similar functionality profiles (Figure S6D). Whereas no significant difference in T-cell frequencies was observed between C/M and C/M/M regimens, these regimens generated significantly greater IFN\( \gamma^+ \) CD4\(^+\) T-cell responses compared to the P/P/P regimen (\( \text{p} = 0.0175 \)), which positively correlated with nAb titers (\( r = 0.4341; \text{p} = 0.0435 \); Figure 3G). Overall, a single bivalent MVA boost vaccine generated the highest nAb titers while inducing a robust polyfunctional CD4\(^+\) and CD8\(^+\) T-cell response, in contrast to a third vaccination (MVA or E2Δ123HMW protein) or three sequential E2Δ123HMW protein vaccinations.

For ease of reference, a comparison of each vaccine regimen tested, alongside HCV-specific T-cell and Ab responses, is shown in a heatmap (Figure 4).

DISCUSSION

HCV vaccine strategies have so far used viral vectors or proteins to generate T-cell or nAb responses, respectively. However, bivalent viral vectored vaccines encoding multiple conserved-sequence Ags may generate pan-genotypic T cells and nAbs, reduce the number of vaccines required, and use established Good Manufacturing Practice facilities to reduce costs and enhance the scalability of vaccine production for human trials.

As a prerequisite to developing a bivalent viral vector vaccine, we show that a ChAdOx1 vector encoding E2Δ123 generated a greater Ab titer after a single vaccination and enhanced CD81 binding-inhibitory and nAb titers when combined with E2Δ123HMW protein vaccine boosts compared to a homologous protein prime-boost regimen, consistent with previous reports.[29] Chmielewska et al. reported that both an Ad6E2662 and Ad6E1E2p7 prime plus two E1E2 protein boosts induced only modest nAbs in mice and did not increase nAb titers compared to three subsequent protein vaccinations in guinea pigs.[30] Consistent with Chmielewska et al. and other reports of varying nAb titers using different E1/E2 forms,[31,32] our result highlights the importance of generating nAbs using an optimized E2 construct.

A ChAd-E2Δ123 prime also broadened the Ab isotype repertoire compared to protein vaccines. T follicular helper cells (Tfh) play a critical role in GC-mediated response, and the reciprocal IgG1/IgG2a titer may be used as a surrogate marker to measure levels of GC-mediated Ab class switching. This was significantly lower for ChAd-E2Δ123 immune sera than E2Δ123HMW immune sera, indicating greater levels of ChAd-induced class switching and GC activity. Generating broad Ab isotype repertoires using viral vectors was also reported using Ad6 in HCV[30] and ChAd63 and MVA in malaria.[33] It is expected that increased GC activity generates higher-affinity Abs through somatic hypermutation, which may enhance Ab neutralizing activity against viral infection. Although we did not directly enumerate Tfh, our data suggest that a ChAd-E2Δ123 prime alters GC-mediated Ab response. Assessment of
the bivalent vector vaccine further revealed that CD4+ T-cell frequencies positively correlated with nAb titers, suggesting that an HCV vaccine that generates CD4+ T cells may enhance nAbs production.

Next, we show that ChAd and MVA vectors encoding the bivalent immunogen, Gt1-6-E2Δ123, used as the prime/boost, elicited high-titer Abs, comparable to a monovalent ChAd-E2Δ123 prime, MVA-E2Δ123 boost
regimen, with no difference detected in CD81-inhibitory and HCVpp-neutralizing titers. Furthermore, the prime/boost bivalent regimen generated a comparable gt-1a-specific and superior gt-1b-specific anti-E2 CD4+ T-cell response compared to the prime/boost monovalent vaccines, likely attributable to T-cell targeting of pan-gt E2 epitopes in the Gt1-6 immunogen, with additional CD4+ and CD8+ T cells targeting conserved NS3-5 epitopes. The monovalent E2Δ123 vaccines generated a greater gt-1a-specific anti-E2 CD8+ T-cell response than the bivalent E2Δ123-Gt1-6 vaccines, possibly explained by the absence of immunodominant NS3-5 CD8 epitopes in the monovalent E2Δ123 vaccine enabling subdominant E2 epitopes to induce CD8+ T cells.

When comparing the prime/boost bivalent vaccine regimen with the prime/boost monovalent T-cell vaccine regimen (Gt1-6 encoded only), the bivalent vaccine regimen generated higher CD8+ and CD4+ T-cell frequencies targeting gt-1a, -tb, and -3a epitopes. Surprisingly, bivalent vaccines increased NS3-5-specific T-cell responses compared to monovalent vaccines despite both immunogens containing the same Gt1-6 epitopes—possible explanations for this include: (1) the potential additive effect of generating of E2Δ123-specific T/B cells, which may have a bystander effect on NS-specific T/B cells, a mechanism recently observed for the p30 T-cell helper epitope (34) or (2) the furin 2A sequence (encoded between the Gt1-6 and E2Δ123 sequences in the ChAd vector to generate two cleaved polypeptides during translation) is not 100% effective and therefore any noncleaved polypeptide may affect Ag stability, proteasomal processing, major histocompatibility complex cross-presentation, and increase the overall immunogenicity compared to monovalent vaccines. Overall, consistent with a reported bivalent flu vaccine, (35) the prime/boost bivalent HCV vaccine regimen generated robust Ab and T-cell responses comparable to immune responses induced by both the monovalent Gt1-6 and E2Δ123 prime/boost vaccine regimens.

To assess the effect of a third vaccination, we administered the bivalent immunogen as a ChAd-Gt1-6-E2Δ123 prime, MVA-Gt1-6-E2Δ123 boost (C/M), with an additional MVA-Gt1-6-E2Δ123 boost (C/M/M), E2Δ123, protein vaccine boost (C/M/P), or no additional boost (C/M/-). These regimens were also compared against three protein immunizations (P/P/P), a regimen historically used to elicit high-titer nAbs. We demonstrate that a ChAd-Gt1-6-E2Δ123 prime, MVA-Gt1-6-E2Δ123 boost (C/M) generates significantly higher nAb and Ab titers to E2Δ123 compared to three E2Δ123, protein immunizations. An additional MVA-Gt1-6-E2Δ123 or E2Δ123, protein third vaccination did not increase Ab titers, contrary to some studies, but consistent with others. Previous studies using three or four immunizations have spaced vaccinations three weeks apart. However, in this study, the C/M/M, C/M/P, and P/P/P vaccinations were deliberately spaced further apart to allow B-cell maturation and somatic hypermutation to increase Ab affinity and nAb activity. Despite achieving higher Ab titers, nAb activity declined at week 22, suggesting an increase in nonfunctional Ab specificities. This suggests that the timing of booster vaccines must be carefully evaluated in future immunization regimens using this approach.
As expected, regimens using viral vector vaccines generated HCV-specific CD4+ and CD8+ T-cell responses that were significantly higher than the protein-only regimen. A ChAd-Gt1-6-E2Δ123 prime, MVA-Gt1-6-E2Δ123 boost generated T-cell responses that were sustained for up to 12 weeks post-MVA. An additional bivalent MVA or E2Δ123 ΔHMW protein third immunization did not further enhance the T-cell response, in keeping with previous reports. [37,38,40] Given that the bivalent HCV vaccine contains subdominant T-cell epitopes within the Gt1-6 immungen [24] it is possible that these epitopes may be readily boosted by other vaccines modalities, such as virus-like particles and nanoparticles. These approaches may be explored in future studies.

The lack of robust, immune-competent small animal models to test HCV vaccine candidates remains a critical block in the field. The rat hepacivirus model is one model that we are currently exploring. [41,42] This model may be used to assess vaccine strategies using an HCV-analogous viral challenge. However, ultimately, in the absence of an immune-competent small animal model that supports robust HCV replication and recapitulates the pathogenesis of HCV, vaccine efficacy will be dependent on phase II human efficacy studies or the development of human challenge models.

In summary, a bivalent viral vector vaccine encoding two sequence-optimized immunogens (E2Δ123 and conserved segment Gt1-6 sequence) may be an optimal regimen to generate a balanced polyfunctional T-cell and high-titer nAb response. Developing vaccination strategies that combine two immunogens to generate T-cell and nAb responses from a single construct has broader importance for the development of vaccines against other pathogens. Future studies assessing mRNA to deliver pan-genotypic T- and B-cell immunogens could be used as alternative, or in addition to, prime/boost strategies with viral-vectored vaccines. Several studies have demonstrated that one of the best-performing COVID-19 vaccine regimens is ChAdOx1 prime followed by an mRNA boost with high spike-specific broadly nAb, IgG, and IgA titers alongside CD4+ and CD8+ T cells. [43–45] The use of ChAdOx1-delivered Gt1-6-E2Δ123 followed by an mRNA Gt1-6-E2Δ123 boost may prove to be an optimal regimen for the generation of HCV-specific T- and B-cell responses.

ACKNOWLEDGMENT

The views expressed in this article, choice of journal to publish the work, writing of the manuscript, and collection, analysis, and interpretation of the data are those of the authors and not necessarily those of the NHS, NIHR, or Department of Health. We thank the staff at the Viral Vector Core Facility (Oxford) for their assistance and expertise in vaccine production. HCV peptides were obtained through the NIH Biodefense and Emerging Infections Research Resources Repository, NIAID, NIH: Peptide Array, Hepatitis C Virus, H77, J4, and K3a650. We also thank Prof. Jens Bukh for providing the gt-3a E1E2 HCVpp clone and the chimeric 3a and 5a HCVcc clone. The graphical abstract was created with BioRender.com.

CONFLICT OF INTEREST

T.D., S.C., and E.B. are all contributors or inventors on patent PCT/GB2017/050840 that describes the conserved segment HCV Gt1-6 T-cell vaccine used in this study. H.D. and P.P. are named inventors on patents PCT/AU2007/001221 and PCT/AU2011/001534 that describe E2 antigens used in this study. H.D., E.B., and S.C. are named inventors of PCT/AU2021/050437.

AUTHOR CONTRIBUTIONS

Conceptualization: Timothy Donnison, Joey McGregor, Senthil Chinnakannan, Rob J. Center, Pantelis Poumbourios, Paul Klenerman, Heidi E. Drummer, and Eleanor Barnes. Data curation: Timothy Donnison and Joey McGregor. Formal analysis: Timothy Donnison, Joey McGregor, Heidi E. Drumme, and Eleanor Barnes. Supervision: Rob J. Center, Senthil Chinnakannan, Pantelis Poumbourios, Heidi E. Drummer, and Eleanor Barnes. Investigation: Timothy Donnison and Joey McGregor. Methodology: Timothy Donnison, Joey McGregor, Senthil Chinnakannan, Claire Hutchings, Rob J. Center, Pantelis Poumbourios, Paul Klenerman, Heidi E. Drummer, and Eleanor Barnes. Resources: Pantelis Poumbourios, Paul Klenerman, Heidi E. Drummer, and Eleanor Barnes. Visualization: Timothy Donnison and Joey McGregor. Writing – original draft: Timothy Donnison. Writing – review and editing: Timothy Donnison, Joey McGregor. Senthil Chinnakannan, Rob J. Center, Claire Hutchings, Pantelis Poumbourios, Paul Klenerman, Heidi E. Drummer, and Eleanor Barnes.

ORCID

Timothy Donnison © https://orcid.org/0000-0001-6568-7761
Joey McGregor © https://orcid.org/0000-0001-6287-684X
Senthil Chinnakannan © https://orcid.org/0000-0002-4404-0229
Claire Hutchings © https://orcid.org/0000-0002-7858-6924
Rob J. Center © https://orcid.org/0000-0002-4466-1922
Pantelis Poumbourios © https://orcid.org/0000-0002-2772-1962
Paul Klenerman © https://orcid.org/0000-0003-4307-9161
REFERENCES

1. Hill AM, Nath S, Simmons B. The road to elimination of hepatitis C: analysis of cures versus new infections in 91 countries. J Virus Erad. 2017;3:117–23.

2. World Health Organization. Global Hepatitis Report 2017. Geneva, Switzerland: World Health Organization; 2017.

3. Stone J, Martin NK, Hickman M, Hallard M, Scott N, McBryde E, et al. The potential impact of a hepatitis C vaccine for people who inject drugs: is a vaccine needed in the age of direct-acting antivirals? PLoS One. 2016;11:e0156213.

4. Major M, Gutfraind A, Shekhtrman L, Cui Q, Kachko A, Cotter SJ, et al. Modeling of patient virus titers suggests that availability of a vaccine could reduce hepatitis C virus transmission among injecting drug users. Sci Transl Med. 2018;10:eaaq4496.

5. Scott N, McBryde E, Vickerman P, Martin NK, Stone J, Drummer H, et al. The role of a hepatitis C virus vaccine: modelling the benefits alongside direct-acting antiviral treatments. BMC Med. 2015;13:198.

6. Lauer GM, Walker BD. Hepatitis C virus infection. N Engl J Med. 2001;345:41–52.

7. Osburn WO, Fisher BE, Dowd KA, Urban G, Liu L, Ray SC, et al. Spontaneous control of primary hepatitis C virus infection and immunity against persistent reinfection. Gastroenterology. 2010;138:315–24.

8. McKiernan SM, Hagan R, Curry M, McDonald GSA, Kelly A, Folgori A, Capone S, et al. Vaccination of chimpanzees against infection by the hepatitis C virus. Proc Natl Acad Sci U S A. 1994;91:1294–8.

9. Lauer GM, Barnes E, Lucas M, Timm J, Ouchi K, Kim Ay, et al. High resolution analysis of cellular immune responses in resolved and persistent hepatitis C virus infection. Gastroenterology. 2004;127:924–36.

10. Pestka JM, Zeisel MB, Blaser E, Schürmann P, Bartosch B, Cosset FL, et al. Rapid induction of virus-neutralizing antibodies and viral clearance in a single-source outbreak of hepatitis C. Proc Natl Acad Sci U S A. 2007;104:6025–30.

11. Osburn WO, Snider AE, Wells BL, Latanich R, Bailey JR, Thomas DL, et al. Clearance of hepatitis C infection is associated with the early appearance of broad neutralizing antibody responses. Hepatology. 2014;59:2140–51.

12. Grakoui A, Shoukry NH, Woollard DJ, Han JH, Hanson HL, Ghrayeb J, et al. HCV persistence and immune evasion in the absence of memory T cell help. Science. 2003;302:659–62.

13. Shoukry NH, Grakoui A, Houghton M, Chien DY, Ghrayeb J, Reimann KA, et al. Memory CD8+ T cells are required for protection from persistent hepatitis C virus infection. J Exp Med. 2003;197:1645–55.

14. Choo QL, Kuo G, Ralston R, Weiner A, Chien D, Van Nest G, et al. Vaccination of chimpanzees against infection by the hepatitis C virus. Proc Natl Acad Sci U S A. 1994;91:1294–8.

15. Frey SE, Houghton M, Coates S, Abruignani S, Chien D, Rosa D, et al. Safety and immunogenicity of HCV E1/E2 vaccine adjuvanted with MF59 administered to healthy adults. Vaccine. 2010;28:6367–73.

16. Law JLM, Chen C, Wong J, Hockman D, Santer DM, Frey SE, et al. A hepatitis C virus (HCV) vaccine comprising envelope glycoproteins gpE1/gpE2 derived from a single isolate elicits broad cross-genotype neutralizing antibodies in humans. PLoS One. 2013;8:e79776.

17. Ray R, Meyer K, Banerjee A, Basu A, Coates S, Abruignani S, et al. Characterization of antibodies induced by vaccination with hepatitis C virus envelope glycoproteins. J Infect Dis. 2010;202:862–6.

18. Folgori A, Capone S, Ruggeri L, Meola A, Sporeno E, Ercole BB, et al. A T-cell HCV vaccine eliciting effective immunity against heterologous virus challenge in chimpanzees. Nat Med. 2006;12:190–7.

19. Barnes E, Folgori A, Capone S, Swadling L, Aston S, Kurioka A, et al. Novel adenovirus-based vaccines induce broad and sustained T cell responses to HCV in man. Sci Transl Med. 2012;4:115ra1.

20. Swadling L, Capone S, Antrobus RD, Brown A, Richardson R, Newell EW, et al. A human vaccine strategy based on chimpanzee adenoviral and MVA vectors that primes, boosts, and sustains functional HCV-specific T cell memory. Sci Transl Med. 2014;6:261ra153.

21. Bailey JR, Barnes E, Cox AL. Approaches, progress, and challenges to hepatitis C vaccine development. Gastroenterology. 2019;156:418–30.

22. Kelly C, Swadling L, Brown A, Capone S, Folgori A, Salmo M, et al. Cross-reactivity of hepatitis C virus specific vaccine-induced T cells at immunodominant epitopes. Eur J Immunol. 2015;45:309–16.

23. Page K, Melia MT, Veenhuis RT, Winter M, Rousseau KE, Massacci G, et al. Randomized trial of a vaccine regimen to prevent chronic HCV infection. N Engl J Med. 2021;384:541–9.

24. Donnison T, van Delft A, Brown A, Swadling L, Hutchings C, Hanke T, et al. Viral vectored hepatitis C virus vaccines generate pan-genotypic T cell responses to conserved subdominant epitopes. Vaccine. 2020;38:5036–48.

25. van Delft A, Donnison TA, Lourenço J, Hutchings C, Mullarkey CE, Brown A, et al. The generation of a simian adenoviral vectored HCV vaccine encoding genetically conserved gene segments to target multiple HCV genotypes. Vaccine. 2019;36:313–21.

26. Viettheer PT, Boo I, Gu J, McCaffrey K, Edwards S, Owczarek C, et al. The core domain of hepatitis C virus glycoprotein E2 generates potent cross-neutralizing antibodies in guinea pigs. Hepatology. 2017;65:1117–31.

27. Alhammad Y, Gu J, Boo I, Harrison D, McCaffrey K, Viettheer PT, et al. Monoclonal antibodies directed toward the hepatitis C virus glycoprotein E2 detect antigenic differences modulated by the N-terminal hypervariable region 1 (HVR1), HVR2, and intergenotypic variable region. J Virol. 2015;89:12245–61.

28. Drummer HE, Maerz A, Pombourhis P. Cell surface expression of functional hepatitis C virus E1 and E2 glycoproteins. FEBS Lett. 2003;546:385–90.

29. de Cassan SC, Draper SJ. Recent advances in antibody-inducing poxviral and adenoviral vectored vaccine delivery platforms for difficult disease targets. Expert Rev Vaccines. 2013;12:365–78.

30. Chmielewska AM, Naddeo M, Capone S, Annemolda V, Hu KE, Meredith L, et al. Combined adenovirus vector and hepatitis C virus envelope protein prime-boost regimen elicits T cell and neutralizing antibody immune responses. J Virol. 2014;88:5502–10.

31. Marin MQ, Sliepen K, Garcia-Arribaza J, Koekkoek SM, Perez P, Sorzano COS, et al. Optimized hepatitis C virus (HCV) E2 glycoproteins and their immunogenicity in combination with MVA-HCV. Vaccines. 2020;8:440.

32. Ruwona TB, Giang E, Nieuisma T, Law M. Fine mapping of murine antibody responses to immunization with a novel soluble form of hepatitis C virus envelope glycoprotein complex. J Virol. 2014;88:10459–71.

33. Douglas AD, de Cassan SC, Dicks MDJ, Gilbert SC, Hill AVS, Draper SJ. Tailoring subunit vaccine immunogenicity: maximizing antibody and T cell responses by using combinations of adenovirus, poxvirus and protein-adjuvant vaccines against Plasmodium falciparum MSP1. Vaccine. 2010;28:7167–78.

34. Swartz AM, Congdon KL, Nair SK, Li QJ, Herndon JE, Suryadevara CM, et al. A conjoined universal helper epitope can unveil antitumor effects of a neoantigen vaccine targeting an MHC class I-restricted neoeptope. NPJ Vaccines. 2021;6:12.
35. Tully CM, Chinnakannan S, Mullarkey CE, Ulaszewska M, Ferrara F, Temperton N, et al. Novel bivalent viral-vectorized vaccines induce potent humoral and cellular immune responses conferring protection against stringent influenza A virus challenge. J Immunol. 2017;199:1333–41.

36. Hodgson SH, Choudhary P, Elias SC, Milne KH, Rampling TW, Biswas S, et al. Combining viral vectored and protein-in-adjuvant vaccines against the blood-stage malaria antigen AMA1: report on a phase 1a clinical trial. Mol Ther. 2014;22:2142–54.

37. Bliss CM, Bowyer G, Anagnostou NA, Havelock T, Snudden CM, Davies H, et al. Assessment of novel vaccination regimens using viral vectored liver stage malaria vaccines encoding ME-TRAP. Sci Rep. 2018;8:3390.

38. Capone S, Reyes-Sandoval A, Naddeo M, Siani L, Ammendola V, Rollier CS, et al. Immune responses against a liver-stage malaria antigen induced by simian adenoviral vector AdCh63 and MVA prime-boost immunisation in non-human primates. Vaccine. 2010;29:256–65.

39. Center RJ, Boo I, Phu L, McGregor J, Poumbourios P, Drummer HE. Enhancing the antigenicity and immunogenicity of monomeric forms of hepatitis C virus E2 for use as a preventive vaccine. J Biol Chem. 2020;295:7179–92.

40. Capone S, Brown A, Hartnell F, Sorbo MD, Traboni C, Vassilev V, et al. Optimising T cell (re)boosting strategies for adenoviral and modified vaccinia Ankara vaccine regimens in humans. NPJ Vaccines. 2020;5:94.

41. Billerbeck E, Wolffsberg R, Fahnøe U, Xiao JW, Quirk C, Luna JM, et al. Mouse models of acute and chronic hepacivirus infection. Science. 2017;357:204–8.

42. Atcheson E, Li W, Bliss CM, Chinnakannan S, Heim K, Sharpe H, et al. Use of an outbred rat hepacivirus challenge model for design and evaluation of efficacy of different immunization strategies for hepatitis C virus. Hepatology. 2020;71:794–807.

43. Barros-Martins J, Hammerschmidt SI, Cossmann A, Odai I, Stankov MV, Morillas Ramos G, et al. Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination. Nat Med. 2021;27:1525–9.

44. Schmidt T, Klemis V, Schub D, Mihm J, Helscher F, Marx S, et al. Immunogenicity and reactogenicity of heterologous ChAdOx1 nCoV-19/mRNA vaccination. Nat Med. 2021;27:1530–5.

45. Borobia AM, Carcas AJ, Pérez-Olmeda M, Castaño L, Bertran MJ, García-Pérez J, et al. Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial. Lancet. 2021;398:121–30.

SUPPORTING INFORMATION
Additional supporting information may be found in the online version of the article at the publisher’s website.

How to cite this article: Donnison T, McGregor J, Chinnakannan S, Hutchings C, Center RJ, Poumbourios P, et al. A pan-genotype hepatitis C virus viral vector vaccine generates T cells and neutralizing antibodies in mice. Hepatology. 2022;76:1190–1202. https://doi.org/10.1002/hep.32470